Interventional cardiology is the catheter-based treatment of cardiovascular diseases. Certified cardiologists who perform these procedures are known as intervention cardiologists. https://www.researchonglobalmarkets.com/global-interventional-cardiology-market-2014-2022.html For the full report please write to info@netscribes.com

1. Prepared by Netscribes (Research on Global Markets)
Proprietary and Confidential, Copyright © 2017, Netscribes, Inc. All Rights Reserved
The content of this document is confidential and meant for the review of the recipient.
Disclaimer: The names or logos of other companies and products mentioned herein are the trademarks of their respective owners
Global Interventional Cardiology Market (2014-2022)
December, 2017
Sample pages

2. Chapter 1: Executive Summary
2

3. 3
Market Scope and Segmentation
InterventionalCardiologyMarket
Segments Differentiation
Product Types
Stents
Catheters
Others
Application
Angioplasty
Valvuloplasty
Region
North America
Europe
Latin America
Middle East and Africa
Asia Pacific

4. 4
Key Questions Answered in This Study
InterventionalCardiologyMarket
 What is the history of interventional cardiology and how has it evolved?
 What is the global market revenue of the Interventional Cardiology market?
 What is the future of the Interventional Cardiology market?
 What are the factors instrumental in changing the market scenario?
 What are the drivers, restraints and trends in the market?
 What is the competitive scenario of the global Interventional Cardiology market?
 What are the strategies of the key market players?
 How have competitors performed in 2016?
 What are the different types of devices and application areas in the Interventional
Cardiology market?
 What are the respective market shares and the opportunities associated with Interventional
Cardiology products in various regions around the world?
 What are the regions with maximum opportunity for the growth of the Interventional
Cardiology market? Which are the countries in those regions with maximum opportunities?
 What are the factors that affect the global Interventional Cardiology market?
 What are the investment opportunities for the Interventional Cardiology market?

5. 5
Executive Summary
Definition
Competition
XX.XX
XX.XX
XX.XX
2014 2017 2022
$ bn
• Interventional cardiology is the catheter-based treatment of heart diseases. Interventional cardiologists are certified cardiologists performing
Interventional Cardiology procedures, mostly in specialized catheterization laboratories in hospitals.
• Interventional Cardiology procedures are minimally invasive in nature.
• During the process, the catheter is directed towards the area affected by using real-time X-ray.
• Stents account for a significant share of the market owing to its ease of use, low cost, and technological advancements - advent of
bioabsorbable stents and bioabsorbable vascular scaffold.
• Catheters segment is likely to grow at a considerable pace owing to their varied application areas.
• By application, angioplasty segment held the maximum market share due to the growing prevalence of cardiovascular diseases
and rising adoption of angioplasty procedures around the world. However, blood clotting or thrombosis has been observed in
some cases of angioplasty procedures. This might restrain the growth of the market to some extent.
• The development of transcatheter aortic valve replacement (TAVR) is likely to drive the growth of the valvuloplasty application
segment in the coming years.
• In the global Interventional Cardiology market, Medtronic PLC held the maximum share of the market followed by Abbott
Laboratories. These two players occupied half of the total market share in the global market.
• Boston Scientific, in the third place, lost its position to Abbott after the latter acquired St. Jude. Medical. Edwards Lifesciences and
Johnson and Johnson Pvt. Ltd. held significant market shares in the global Interventional Cardiology market as well.
• North America held the maximum share in the global interventional cardiology market followed by Asia Pacific.
• Asia Pacific is expected to grow at a considerable rate over the forecast period owing to surge in population, increase in health
spends, and growing number of people having cardiovascular diseases.
• Other regions covered in the report are Europe, Latin America, and Middle East and Africa.

6. Chapter 2: Introduction - Interventional Cardiology Market
6

7. 7
• Prototype
• Process
Development
• Regulatory
Approval
• Product
Engineering
Components
Manufacturing
Distribution
Marketing and Sales
Value Chain Analysis
Post Sales
Services
Input Suppliers Buyers
• Software
Development
• Precision Metal
Works
• Plastics Extrusion,
Moulding
• Assembly
• Packaging
• Sterilization
Final Products
• Interventional
Cardiology
Devices
• Surgical
Instruments
• Others
• Training
• Consulting
• Maintenance,
Repair
Wholesalers
Hospitals
Doctors and
Nurses
Individual
Patients
MetalsChemicals
Research and Product
Development
Companies operating in the global Interventional Cardiology market are expanding their product portfolios to keep up with the rapidly changing market demand and increasing product life cycles. For instance,
emerging economies demand more economical products. Compliance issues are on the rise as products are going through more complex and strict regulatory scrutiny. The sector could decrease its production lead
times, while manufacturers, hospitals, pharmacies and distributors could hold significantly smaller inventories. This would improve the healthcare supply chain and help millions of patients around the world by
passing on benefits to consumers.
Some companies in the Interventional Cardiology devices field are trying to reduce costs in order to improve their margin. In emerging as well as established markets, device makers are turning to third-party supply
chain partners. This initiative, in turn, helps to simplify the complexities of the international logistics landscape. Additionally, it delivers products more quickly, inexpensively and efficiently to patients and healthcare
professionals who need them.
Market Segments
• Cardiovascular
(Stents,
Catheters)
• Orthopaedics
• Others
Assembly

8. Chapter 4: Interventional Cardiology Market Overview

9. 9
Global - Market Overview
XX.X
XX.X
XX.X
2014 2015 2016
XX.X XX.X
XX.X
XX.X
XX.X
XX.X
2017 2018 2019 2020 2021 2022
Key Market
Drivers
Fig 1: Global historical market revenue (US$ bn) Fig 2: Global forecasted market revenue (US$ bn)
CAGR (2014-2017): X.X% CAGR (2018-2022): X.X%
The higher incidence of CVD (cardiovascular disease) is because of an increase in familiar risk factors such as hypertension, dyslipidemia (high cholesterol), smoking, obesity, diabetes, and
sedentary lifestyle. These factors give rise to cardiovascular ailments, including devastating heart attacks. The increase in the number of cardiovascular diseases is expected to drive the growth of
the Interventional Cardiology market over the forecasted period.
• Minimally invasive procedures are operational
processes in which the surgeon operates
between the ribs of the patient through small
incisions (rather than cut through the
breastbone).
• Some of the advantages of this procedure are
reduced post-operative discomfort, less blood
loss, lowered risk of infections and faster healing
times. They eliminate the possibility of deep
sternal wound infections as well.
• The development of advanced minimally-invasive
procedures and an increase in its adoption in
interventional cardiology is likely to drive the
global market in the future.
• Clotting in a blood vessel is known as thrombosis. Drug-eluting stents may result in thrombosis. Moreover, in situations of procedural complexities,
bioabsorbable stents have not been as effective as initial projections. Other problems include. varying rates of degradation and uneven release of the drug in
the patient’s body
• The global Interventional Cardiology market is very dynamic. The intensity of competition among the market players is relatively high. Additionally, the price
cuts offered by small and medium players on their devices is compelling the established companies to reduce their profit margins. These factors have led to the
inhibition of the research and development efforts owing to lack of funds.
• Some of the other restraining factors include limited insurance coverage (especially in the developing countries), and some cases of death(.1%), hematoma (1-
3%), infection (0.2%), blood clot, and bleeding.
Market Challenges

10. Global - Market Drivers
Impact
High Medium Low
Number of Patients
• Globally, the number of patients with cardiovascular disease is increasing at a fast pace.
• According to WHO, almost 23.3 million deaths are expected to occur by 2030 on account of cardiovascular diseases.
• This increase is primarily due to the following factors: increasing percentage of the geriatric population and the
growing obesity epidemic, especially in developed nations. Both these factors are responsible for the rising number
of heart diseases in the world at present.
3
Hybrid Procedures
• The rising popularity of hybrid procedures will drive the growth of
the global Interventional Cardiology market over the forecast
period. Hybrid processes/procedures are a combination of
catheter-based and surgical intervention to the heart for the
treatment of cardiovascular diseases.
• According to industry experts, one of the major factors
responsible for the rising inclination for hybrid procedures is their
ability to obliterate plaque from the blood vessels. It offers long-
term benefits to the patients as well.
Procedural Efficiency
• In the current scenario, the advancements in the field of cardiology
have made Interventional Cardiology procedures uncomplicated,
undemanding and unchallenging.
• These procedures cause less pain than the conventional cardiology
procedures, the risk of infection is low, and large scars are avoided.
Moreover, in many cases, patients remain awake during the process.
• These factors have increased the confidence of the patients towards
Interventional Cardiology procedures. The percentage of cardiac
patients undergoing surgery has grown in the past years and is likely to
develop considerably in the years to come, thereby increasing the
overall growth of the Interventional Cardiology market.
1
2
10

11. Global - Market Trends
Impact
High Medium Low
Technology
• Latest technological advancements such as 3D printing, nanotechnology, and total artificial heart are likely to have a positive impact on
the global Interventional Cardiology market.
• In the field of structural heart disease, TAVR or transcatheter aortic valve replacement and the MitraClip and Watchman devices are
being tested to integrate them into more routine care. Their real-world performance is going to be monitored for safety and efficacy.
The next possible area that is explored is non-operative mitral valve replacement. It is likely to encourage more and more patients to
undergo interventional surgeries, increasing the demand for Interventional Cardiology procedures.
Bioabsorbable stent
• The bioabsorbable stent has become the preferred choice of
interventional cardiologists in the treatment of cardiovascular
diseases. It has become the prevalent type of drug-eluting stent
used in the treatment of cardiovascular diseases.
• Present-day stents have transformed the practice of
interventional cardiology. The cost of these stents has recently
been standardized, which has led to an increase in the adoption of
these stents.
• Bioabsorbable stents have acquired a significant place in the
treatment armamentarium of interventional cardiology.
Health Promotion
• Health promotion, a concept that focuses on understanding general
health from various perspectives, is a significant trend that is emerging
and is likely to grow. Moreover, to manage health and disease, mobile
technology and digital health are likely to evolve in the coming years.
• Investment for the expansion of mobile interfaces in the field of
cardiac health will boost accountability among patients with regard to
their health. Eventually, more patients will opt for interventional
cardiology treatments.
• Currently, these interfaces are used to transmit heart rhythms in
arrhythmia patients.
1
2 3
11

12. Chapter 5: Regional Overview
12

13. 13
North America - Market Overview
Précis
North America
XX.X XX.X 5.35 XX.X XX.X XX.X XX.X XX.X
XX.X
2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR (2017-2022): X.X%
Fig 4: North America Market revenue (US$ bn)
Market Drivers
Major Trends
Increase in the cardiovascular patient pool
• North America and Europe exhibit a high consumption
rate of premium-priced Interventional Cardiology
devices. Moreover, these regions continue to drive
innovations in medical devices that have given them an
advantage over the other regions.
• Cardiovascular disease (CVD) takes lives of around
800,000 people in the United States (one in three
deaths). In this region, an average of one person dies
due to CVD every 40 seconds.
• The majority of CVD deaths takes place in patients with
coronary heart disease (CHD) followed by stroke and
heart failure.
• Expenses associated with cardiovascular diseases are likely to
soar in the future and exceed medical cost estimates for
other diseases such as diabetes and Alzheimer’s.
• North America held the maximum market share in the global
Interventional Cardiology market in 2016. Presence of a large
number of people with cardiovascular diseases along with the
presence of a significant number of manufacturers is some of
the factors responsible for the leading position in this region.
PFO (Patent Foramen Ovale) closure procedures are
expected to pick up in 2017. PFO closure efficacy has
been studied in the RESPECT trial and has beaten
medical management in secondary stroke prevention.
TAVR (Transcatheter Aortic Valve Replacement) is likely
to supersede SAVR (Surgical Aortic Valve Replacement)
as the standard of care for all patients suffering from
severe aortic stenosis, thereby driving the overall
Interventional Cardiology market.
The major risk factors affecting the North American population are smoking, physical
inactivity or sedentary lifestyle, overweight/obesity, hypertension, and dyslipidemia.

14. The United States of America, North America: About 610,000
people die of heart disease in the United States every year–that’s
1 in every four deaths. Availability of advanced healthcare, high
adoption rate of interventional cardiology, large patient pool, and
presence of many established players in the field of interventional
cardiology are some of the factors for this region’s dominance.
European Union, Europe: Data available from across the EU states that, more than a million coronary
angioplasty were conducted in 2015 alone. The next most common procedure was heart bypass surgery.
As the number of procedures for heart-related diseases is likely to rise, so will the number of coronary
angioplasty procedures in this region, of which a significant percentage will be performed via
intervention cardiology.
Leading Countries(contd.)-Interventional Cardiology Market
.14
Japan, Asia Pacific: Japan has always been regarded as
one of the largest markets for cardiovascular devices in
the world, second only to the United States, due to its
advanced health-care system and high pricing.
Asia Pacific: Most device companies regard Japan,
China, and India as their chief targets, the former due
to its wealth and pricing structure, and the others
due to their economic growth and vast population.
Many devices are made available in other parts of
Asia as well, notably Hong Kong and Singapore.
Brazil, Latin America: Latin America’s two largest economies, Brazil,
and Argentina, are growing at a steady economic rate since more
number of people are gaining access to healthcare services and
people can spend more on medical services currently. It is
estimated that 13.8% and 33.7% of the total population in Brazil will
reach the highest life expectancy by 2020 and 2060, respectively.
Saudi Arabia, Middle East: The prevalence of risk factors for HF is
increasing in this region. For example, 26% of the Saudi population is
affected by hypertension, and approximately 24% is affected by diabetes
mellitus. Patients with diabetes are at a higher risk for developing HF;
the Framingham study showed that the risk of HF was 2-fold higher
among men and 5-fold higher among women with diabetes.
South Africa, Africa: Due to the high prevalence of ischemic
heart disease and rheumatic heart disease, coronary
angiography, PTCA, intracoronary stenting, and balloon
valvuloplasty has become established cardiology procedures
in South Africa.

15. Chapter 6: Segmentation Overview-By Product Type

16. 16
Global product overview – Stents
North
America
Asia Pacific
Europe
Latin
America
Middle East
and Africa
2016
US$ XX.XX
bn
North America
Asia Pacific
Europe
Latin America
Middle East and
Africa
2022
US$XX.XX
bn
Revenue contribution – Stents
Stents-Analysis
Stenting has various advantages such as improving blood flow and preventing further damage
to heart cells. Moreover, stenting is much less invasive than other cardiac surgeries.
The price of stents is decreasing, owing to technological developments, and various government initiatives, thereby resulting in a higher adoption rate. For instance, the
National Pharmaceutical Pricing Authority (NPPA) of India issued a notification in February 2017. It capped the price of stents (drug-eluting stent at around US$ 460, former
price range: US$ 620 - US$ 3065; bare-metal stents at just US$ 113, former price range: US$ 465 - US$ 1160). The stent segment in the Asia Pacific is likely to grow at a
significant pace during the forecast period owing to many factors such as increase in geriatric population, favorable government initiatives, and increasing patient awareness.
Top5companiesinthisProductsegment
Medtronic PLC.
Boston Scientific Corporation
Abbott Laboratories, S.A.
Livanova, PLC
Microport Medical Apparatus(Shanghai) Co. Ltd.
Logo
Logo
Logo
Revenue: US$28.83 bnFY 2016
Revenue: US$9.08 bnFY 2016
Revenue: US$20.85bnFY 2016
Revenue: US$1.21 bnFY 2016
Revenue: US$0.40 bnFY 2016

17. Chapter 7: Segmentation Overview-By Application
17

18. 18
Global application overview – Angioplasty
Revenue contribution – Angioplasty
Angioplasty-Analysis
More than 15 million Americans are affected by CAD (Coronary Artery Disease) each year. Angioplasty is the procedure in which
cardiologists open narrowed arteries to treat various CADs. With an increase in the number of old patients, the number of
angioplasties will also rise in the Interventional Cardiology market.
The development of DES and DEB is likely to drive the growth of angioplasty in the forecast period. As the restenosis rate decrease owing
to technological advancements such as laser coronary angioplasty. Laser angioplasty is expected to control the coronary stenosis by
ablation of atherosclerotic plaque. Thus, the future of coronary angioplasty seems promising.
Another futuristic procedure currently under study is the application of adult stem cells at the time of an angioplasty procedure to stop a
heart attack in progress. Scientists are hoping that the outcome of this procedure may be the generation of new heart tissues that might
improve the long-term heart functioning. This procedure will give an immense boost to the angioplasty procedures in the coming years.
Top5companiesinthisProductsegment
Medtronic PLC.
Boston Scientific Corporation
Terumo Corporation
Livanova, PLC
Logo
Logo
Revenue: US$ 28.83 bnFY 2016
Revenue: US$ 9.08 bnFY 2016
Revenue: US$ 4.83bnFY 2016
Revenue: US$ 1.21 bnFY 2016
Microport Medical Apparatus(Shanghai) Co. Ltd.
Revenue: US$ 0.40 bnFY 2016
North
America
Asia Pacific
Europe
Latin
America
Middle East
& Africa
2016
US$ XX.XX
bn
North America
Asia Pacific
Europe
Latin America
Middle East and
Africa
2022
US$XX.XX
bn

19. Chapter 8: Company Profiles

20. MICHAEL J.
COYLE
EVP and President, Cardiac and
Vascular Group
MIKE
GENAU
SVP and President,
Americas Region
HOOMAN
HAKAMI
EVP and President, Diabetes
Group
BRYAN
HANSON
EVP and President, Minimally
Invasive Therapies Group
Management Team: Medtronic Public Limited Company
SCOTT
OSTRANDER
IT Director - Identity &
Access Management
JEFF WYSOCKI
Business Unit CIO / IT
Leader
MICHAEL
HEDGES
VP & Chief
Information Officer
20

21. 21
Company Overview: Medtronic Public Limited Company
Company snapshot
Products/Services
• Year of establishment: 1949
• Headquarters: Dublin, Ireland
• Key People: Omar Ishrak, Chairman and CEO
• Employee Strength (2016): 88,000
• Industry: Medical Devices
• Ticker: NYSE: MDT
• Website: www.medtronic.com
Strategy and Initiatives
Key numbers (2016)
• Net Income: US$ 3,538 mn
• Profit Margin (%): 12.3%
• Gross Margin (%): 68.3%
• Return on Assets (ROA)(%): 3.5%
• Return on Equity (ROE)(%): 55.4%
• Quick Ratio: 1.18x
• Current Ratio: 3.29x
• PE Ratio: 31.85x
• The company focuses on therapy innovation, globalization and creation of
economic value for customers. To pursue that, in June 2014, Medtronic announced
its acquisition of Covidien, PLC of Ireland, after which it moved its headquarters to
low-tax Ireland. Moreover, in October 2017, Medtronic PLC announced that it had
treated the first patient in the landmark transcatheter mitral valve replacement
(TMVR) pivotal trial.
• Medtronic PLC also emphasizes on mergers and acquisitions for obtaining a wide
variety of technologies, products, and capabilities. In February 2016, the company
planned to acquire Bellco to venture into a newly created renal care solutions
division. Furthermore, in June 2016, Medtronic PLC pronounced its acquisition of
HeartWare International Inc. for US$1.1 billion to expand its heart failure portfolio.
• The company’s sales and marketing strategy are concentrated on the rapid and
cost-effective delivery of quality products to different groups of customers
worldwide, including hospitals, physicians, and other medical institutions. In May
2017, Medtronic launched resolute Onyx(TM) Drug-Eluting Stent in the United
States. It became the first DES available in 4.5 mm and 5 mm sizes. Additionally, in
February 2017, Medtronic PLC’s New Solitaire(TM) Stent Retriever Study validated
the outcomes from four pivotal randomized controlled trials (SWIFT PRIME,
ESCAPE, EXTEND IA, REVASCAT), establishing the benefits of mechanical
thrombectomy in patients who suffer from AIS or acute ischemic stroke.
Revenue (2016)
US$ 28,833 Mn
Cardiac and Vascular Group
Restorative Therapies Group
Minimally Invasive Therapies Group
Diabetes Group
28%
12%
35%
33%
25%
07%
Revenue
Contribution
Locations
• Americas
• Europe, the Middle East
and Africa
• Greater China
• Asia Pacific

22. Appendix
22

23. Appendix
Table 11: Latin America Segments by Type (2014 – 2022) value in US$ bn
23
2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR(2017-
2022)
Stents XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%
Catherers XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%
Others XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%
Total XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%
List of Tables
Table 12: Latin America Segments by Application(2014 – 2022) value in US$ BN
2014 2015 2016 2017 2018 2019 2020 2021 2022
CAGR(2017-
2022)
Angioplasty XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%
Valvuloplasty XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%
Total XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX XX.XX X.X%

24. Appendix
24
Research Methodology
The study begins with identifying the right research question(s). The question depends on what we are going to achieve by conducting the research or what we want
to convey to the prospective customers through this research. Next, we identify the logical steps to arrive needed to arrive at the answers to the question(s). These
logical steps form our research objectives. The research objectives provide us a guideline regarding what information we need to conduct analysis. We strongly
believe that well-defined objectives will lead to clear results about the given market
The next stage of the research is conducted utilizing the secondary sources of information, using a process called desk/secondary research. Netscribes Inc. has a
considerable volume of information in both quantitative and qualitative forms, across all major industries and its sectors. Also, we conduct an in-depth study of the
market, understanding its key stakeholders, drivers, trends, challenges and global opportunities covering major regions such as North America, Latin America, Europe,
Asia Pacific, and Middle East & Africa. The key sources referred to for this research includes (but not limited to) the following:
 Financial reports published by the key market players
 Government and other official sources including the National Statistics
 National and International trade associations
 Paid databases
 Other reliable sources
Primary research complements the secondary research as it helps us gain insights from the industries directly by communicating with the senior executives, key
opinion leaders and independent consultants who are experts in their industries or specific industry sectors. Such interviews are conducted across the value chain of
the market in question. A survey questionnaire is usually prepared for conducting any primary interview or survey. The questionnaire is developed with utmost care to
fulfil the key research objectives and also to validate the assumptions about the market. This supplements the information otherwise unaddressed via secondary
research. The primary data collection is done by expert interviewers who have specific industry knowledge. Linguists are hired to conduct interviews in the
respondent’s native language. Only paid interviews are conducted to incentivize the respondents and ensure that there is no shift of focus. Some of the primary
research methods applied at Netscribes include the following:
 In-depth Interviews
 Executive Interviews
 Expert Panels
The qualitative and quantitative findings from the above stages are brought together by specialists to perform a rigorous analysis. The regional market trends, drivers,
and opportunities obtained during the analysis is compared with regional economic indicators, sector growth rates, population index, etc. to ensure data consistency.
After ensuring the consistency, these historical and present indicators help us to understand how the market will perform in future. Our proprietary forecasting model
factors in all these indicators to predict the future market accurately.

25. Appendix
25
Assumptions
 A number of demographic factors such as prevalence of cardiovascular diseases,
population growth, rise in geriatric population, increase in the prevalence of diabetes, etc.
have been taken into consideration.
 For calculating various ratios pertaining to companies, the share price of September 7,
2017 was taken into consideration.
 No significant new competition has been considered while forecasting the market.
 No unexpected changes in the external factors have been considered that could change
the global scenario of the market in the future.
 No major technological development has been taken into consideration that may replace
Interventional Cardiology procedures in the coming years.
 The inflation rate has not been taken into consideration while forecasting the revenue.

26. Appendix
26
About Netscribes Inc.
MBA
28%
Graduates
22%
BE
20%
BCA/MCA
12%
CPA/CA/CFA
8%
Others
10%
Well-qualified Team
Netscribes provides end-to-end research-driven solutions that help clients meet their growth objectives by collaboratively transforming information into business advantage.
In-house Research Data VisualizationGlobal CoveragePanel Expertise Premium Databases
Specialized panel of senior
executives, analysts and
practitioners
Extensive experience of
working on various
premium databases
Ability to conduct research
across the globe in multiple
languages
Ability to present complex
data insights in crisp, easy-
to-understand visuals
Global market
intelligence and content
management firm –
services across the
research and information
value chain
Venture-funded by US
and Singapore private
equity firms
725+ member delivery
team across Mumbai,
Kolkata and Gurgaon, and
sales presence in USA, UK,
Singapore, Dubai and
Israel
Revenue composition:
USA: 45%
Europe/MENA: 45%
APAC: 10%
ISO 9001:2008
certified by DNV GL
since 2014
Owns:
– Inrea Research
– OnSense
– Research on Global
Markets
We utilize an in-house resource
model to provide our clients
with actionable insights

27. Thank You for Your Attention
27
Global Interventional Cardiology Market report is part of Netscribes’ Healthcare Industry Series.
For any queries or customized research requirements, contact us at:
Phone: +91 (33) 4027 6251 | E-Mail: support@researchonglobalmarkets.com
Research on Global Markets is a leading source of research reports on worldwide markets. Sourced from
leading publishers, our reports cover a broad range of industries across international markets to help
customers make informed business decisions. With Research on Global Markets, you can be assured of
relevant, comprehensive market research reports and analysis, as you need it.
Disclaimer: This report is published for general information only. Although high standards have been used in the preparation, “Netscribes” is not responsible for any loss or
damage arising from use of this document. This document is the sole property of Netscribes and prior permission is required for guidelines on reproduction.